KA/EN
Register
Medicines reference
Search
Search
Active substance

Benazepril

Favourites

ACE inhibitor. No registration in force in Georgia. Forms: scored tablet.

Dose and use

Doses

Each dose comes with its source. Check the label of the product you use.

Active substance Benazepril
Dose calculatorCalculates the active-substance amount; it is not a prescription.
PatientSpecies and weight will be filled in automatically in other calculators.
Selected dose
Dose Species Indication Route Frequency Source
0.25–0.5 mg/kg Dog Congestive Heart Failure By mouth once daily
BenazeVet 2.5 mg, VMD SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
BenazeVet 2.5 mg Tablets for Cats and Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
0.5–1 mg/kg Cat Proteinuria in Chronic Kidney Disease By mouth once daily
BenazeVet 2.5 mg, VMD SPC 2025
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
BenazeVet 2.5 mg Tablets for Cats and Dogs - Summary of Product Characteristics
UK Veterinary Medicines Directorate, 2025
Before use

Safety information

Known Contraindications

  • Critical
    Do not use in known cases of hypersensitivity to the active substance or to any of the excipients.
    Sources: VMD SPC · VMD
  • Critical
    Do not use in cases of hypotension, hypovolaemia, hyponatraemia or acute renal failure.
    Sources: VMD SPC · VMD · IRIS
  • Critical
    Do not use in cases of cardiac output failure due to aortic or pulmonary stenosis.
    Sources: VMD SPC · VMD
  • Critical
    Do not use during pregnancy or lactation.
    Sources: VMD SPC · VMD
  • Critical
    Do not use during pregnancy or lactation.
    Sources: VMD SPC · VMD
  • Warning
    Do not use in cases of... acute renal failure.
    Sources: VMD SPC · VMD

Known Drug Interactions

  • Major warning Benazepril + Telmisartan
    Available data in cats with CKD show no known interaction between telmisartan and other drugs acting on the RAAS (ARBs, ACE inhibitors), but combining drugs that act on the RAAS can change kidney function.
    Recommendation: Use an ACE inhibitor and an angiotensin-receptor blocker together only after an individual benefit-risk assessment. Monitor creatinine, potassium, blood pressure, and hydration closely so deterioration in renal function is detected promptly.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Benazepril + Amlodipine
    Both drugs lower blood pressure, so hypotension is theoretically possible when they are combined. In hypertensive cats treated with amlodipine and benazepril together, however, no hypotension caused by the combination has been observed.
    Recommendation: This combination is not prohibited and may be used when one agent does not adequately control blood pressure. Measure blood pressure before treatment and ensure adequate hydration. Target systolic pressure is below 160 mmHg; below 120 mmHg or weakness/tachycardia indicates hypotension.
    Sources: VMD SPC · VMD · IRIS
  • Minor warning Robenacoxib + Benazepril
    When robenacoxib is used with drugs that affect renal blood flow, such as diuretics or angiotensin-converting enzyme inhibitors, monitor the patient clinically.
    Recommendation: Monitor the patient clinically and check renal parameters.
Latin name
Benazepril
Georgian name
ბენაზეპრილი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
0 of 2 forms
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration2

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Benazepril 2.5 mg, Scored tablet

tablet
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Potential oral use of this unidentified generic benazepril tablet as an adjunct in established canine congestive heart failure
Not rateable
No numerical score assigned
vetman assessment

Benazepril 2.5 mg

tablet
Assessed clinical scopeDog · Potential oral use of this unidentified generic benazepril tablet as an adjunct in established canine congestive heart failure · By mouth
Care settingVeterinary-directed long-term adjunctive treatment after cardiac staging and stabilization, with blood pressure, hydration, renal variables, electrolytes and the complete heart-failure regimen reviewed.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: No · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical product score cannot be assigned because catalogue entry 9111 identifies only a generic 2.5 mg benazepril tablet. It gives no trade name, manufacturer or marketing-authorisation holder, authorisation number, pack, exact label or independently verified formulation. Its dose records explicitly borrow the BenazeVet SPC as a comparator. BenazeVet has applicable dog/cat authorisations and substantial clinical evidence, but those facts cannot be transferred to an unidentified tablet to score its regulation, safety, subdivision, palatability, storage or practical dose delivery. Confirm the exact marketed product or convert this record to a verified BenazeVet presentation before numerical scoring.

Benazepril has a legitimate evidence-based adjunctive role in canine congestive heart failure, but current treatment is multimodal and pimobendan- or spironolactone-containing regimens outperform benazepril-centred comparison regimens in key trials. That ingredient-level judgment does not identify or validate this tablet.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, authorisation, bioequivalence, excipients, flavouring, pack or quality from the generic catalogue name.
  • BenazeVet is the documented clinical and dosing comparator, not the identified product in this catalogue row. Its authorisation and product-specific properties must not be represented as belonging to this unidentified tablet.
  • In dogs, use benazepril only as part of a complete, stage-appropriate congestive-heart-failure plan. It is not a substitute for diagnosis, diuresis when congested, pimobendan or other indicated components, and routine use in preclinical MMVD is not uniformly supported.
  • Placebo-controlled evidence supports benefit in canine CHF, but QUEST found longer event-free survival with pimobendan than with benazepril-based conventional therapy, and BESST found spironolactone plus benazepril superior to benazepril alone with furosemide.
  • Do not start an ACE inhibitor in a dehydrated, hypovolaemic or haemodynamically unstable patient. Correct volume deficits first; monitor blood pressure, hydration, creatinine/SDMA, urea and electrolytes after initiation and dose changes.
  • Do not use with hypotension, hypovolaemia, hyponatraemia, acute renal failure, hypersensitivity, or cardiac-output failure caused by aortic or pulmonary stenosis. Safety and efficacy are not established below 2.5 kg for the BenazeVet comparator.
  • Do not use during pregnancy or lactation. Breeding safety is not established and ACE inhibition has recognised fetal risk; prevent accidental ingestion, especially by pregnant people and children.
  • Review NSAIDs, other hypotensive medicines, anaesthetics/sedatives and potassium-sparing diuretics. Monitor renal function, hypotension and potassium; do not assume absence of an interaction merely because common CHF combinations have been used.
  • This generic 2.5 mg row is marked as a scored tablet, but exact equal subdivision, palatability, half-tablet shelf life and storage are properties of a verified formulation. Do not transfer those BenazeVet features until the actual product is identified.
Assessment sources
  1. Benazepril identity audit2026
  2. BenazeVet 2.5 mg, VMD SPC 20252025
  3. ACVIM canine MMVD2019
  4. BENCH canine CHF trial1999
  5. QUEST pimobendan vs benazepril2008
  6. BESST combination trial2021
  7. BENCH canine tolerability2004
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Potential oral use of this unidentified generic benazepril tablet to reduce persistent renal proteinuria associated with feline chronic kidney disease
Not rateable
No numerical score assigned
vetman assessment

Benazepril 2.5 mg

tablet
Assessed clinical scopeCat · Potential oral use of this unidentified generic benazepril tablet to reduce persistent renal proteinuria associated with feline chronic kidney disease · By mouth
Care settingVeterinary-directed long-term treatment only after persistent renal proteinuria is confirmed and dehydration is corrected, with serial UPC, blood pressure, creatinine/SDMA, electrolytes and clinical response monitoring.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: No · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical product score cannot be assigned because catalogue entry 9111 identifies only a generic 2.5 mg benazepril tablet. It gives no trade name, manufacturer or marketing-authorisation holder, authorisation number, pack, exact label or independently verified formulation. Its dose records explicitly borrow the BenazeVet SPC as a comparator. BenazeVet has applicable dog/cat authorisations and substantial clinical evidence, but those facts cannot be transferred to an unidentified tablet to score its regulation, safety, subdivision, palatability, storage or practical dose delivery. Confirm the exact marketed product or convert this record to a verified BenazeVet presentation before numerical scoring.

Benazepril can reduce proteinuria in cats with CKD and is included among RAAS-inhibitor options, but an all-cat survival benefit has not been shown and telmisartan has stronger comparative UPC results. That ingredient-level judgment does not identify or validate this tablet.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, authorisation, bioequivalence, excipients, flavouring, pack or quality from the generic catalogue name.
  • BenazeVet is the documented clinical and dosing comparator, not the identified product in this catalogue row. Its authorisation and product-specific properties must not be represented as belonging to this unidentified tablet.
  • In cats, the supported role is reduction of persistent renal proteinuria associated with CKD, not general treatment of every cat with CKD, not stand-alone control of systemic hypertension and not a proven survival-extending claim.
  • Feline trials support reduction in UPC, but the largest placebo-controlled study did not show a significant overall renal-survival benefit. In an active-comparator trial telmisartan was noninferior and produced significant UPC reductions where benazepril did not.
  • Do not start an ACE inhibitor in a dehydrated, hypovolaemic or haemodynamically unstable patient. Correct volume deficits first; monitor blood pressure, hydration, creatinine/SDMA, urea and electrolytes after initiation and dose changes.
  • Do not use with hypotension, hypovolaemia, hyponatraemia, acute renal failure, hypersensitivity, or cardiac-output failure caused by aortic or pulmonary stenosis. Safety and efficacy are not established below 2.5 kg for the BenazeVet comparator.
  • Do not use during pregnancy or lactation. Breeding safety is not established and ACE inhibition has recognised fetal risk; prevent accidental ingestion, especially by pregnant people and children.
  • Review NSAIDs, other hypotensive medicines, anaesthetics/sedatives and potassium-sparing diuretics. Monitor renal function, hypotension and potassium; do not assume absence of an interaction merely because common CHF combinations have been used.
  • This generic 2.5 mg row is marked as a scored tablet, but exact equal subdivision, palatability, half-tablet shelf life and storage are properties of a verified formulation. Do not transfer those BenazeVet features until the actual product is identified.
Assessment sources
  1. Benazepril identity audit2026
  2. BenazeVet 2.5 mg, VMD SPC 20252025
  3. IRIS 20262026
  4. BENRIC feline CKD trial2006
  5. Feline CKD efficacy trial2006
  6. Telmisartan-benazepril feline trial2015
  7. Feline renal PK/PD2002
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Benazepril2.5 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
-
Product
generic presentation, not registered in Georgia under a trade name
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Not confirmed
Verified on: 15 Oct 2026
 UK Not confirmed
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Benazepril 5 mg, Scored tablet

tablet
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Potential oral use of this unidentified generic benazepril tablet as an adjunct in established canine congestive heart failure
Not rateable
No numerical score assigned
vetman assessment

Benazepril 5 mg

tablet
Assessed clinical scopeDog · Potential oral use of this unidentified generic benazepril tablet as an adjunct in established canine congestive heart failure · By mouth
Care settingVeterinary-directed long-term adjunctive treatment after cardiac staging and stabilization, with blood pressure, hydration, renal variables, electrolytes and the complete heart-failure regimen reviewed.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: No · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical product score cannot be assigned because catalogue entry 9112 identifies only a generic 5 mg benazepril tablet. It gives no trade name, manufacturer or marketing-authorisation holder, authorisation number, pack, exact label or independently verified formulation. Its dose records explicitly borrow the BenazeVet SPC as a comparator. BenazeVet has applicable dog/cat authorisations and substantial clinical evidence, but those facts cannot be transferred to an unidentified tablet to score its regulation, safety, subdivision, palatability, storage or practical dose delivery. Confirm the exact marketed product or convert this record to a verified BenazeVet presentation before numerical scoring.

Benazepril has a legitimate evidence-based adjunctive role in canine congestive heart failure, but current treatment is multimodal and pimobendan- or spironolactone-containing regimens outperform benazepril-centred comparison regimens in key trials. That ingredient-level judgment does not identify or validate this tablet.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, authorisation, bioequivalence, excipients, flavouring, pack or quality from the generic catalogue name.
  • BenazeVet is the documented clinical and dosing comparator, not the identified product in this catalogue row. Its authorisation and product-specific properties must not be represented as belonging to this unidentified tablet.
  • In dogs, use benazepril only as part of a complete, stage-appropriate congestive-heart-failure plan. It is not a substitute for diagnosis, diuresis when congested, pimobendan or other indicated components, and routine use in preclinical MMVD is not uniformly supported.
  • Placebo-controlled evidence supports benefit in canine CHF, but QUEST found longer event-free survival with pimobendan than with benazepril-based conventional therapy, and BESST found spironolactone plus benazepril superior to benazepril alone with furosemide.
  • Do not start an ACE inhibitor in a dehydrated, hypovolaemic or haemodynamically unstable patient. Correct volume deficits first; monitor blood pressure, hydration, creatinine/SDMA, urea and electrolytes after initiation and dose changes.
  • Do not use with hypotension, hypovolaemia, hyponatraemia, acute renal failure, hypersensitivity, or cardiac-output failure caused by aortic or pulmonary stenosis. Safety and efficacy are not established below 2.5 kg for the BenazeVet comparator.
  • Do not use during pregnancy or lactation. Breeding safety is not established and ACE inhibition has recognised fetal risk; prevent accidental ingestion, especially by pregnant people and children.
  • Review NSAIDs, other hypotensive medicines, anaesthetics/sedatives and potassium-sparing diuretics. Monitor renal function, hypotension and potassium; do not assume absence of an interaction merely because common CHF combinations have been used.
  • This generic 5 mg row is marked as a scored tablet, but exact equal subdivision, palatability, half-tablet shelf life and storage are properties of a verified formulation. Do not transfer those BenazeVet features until the actual product is identified.
Assessment sources
  1. Benazepril identity audit2026
  2. BenazeVet 5 mg, VMD SPC 20252025
  3. ACVIM canine MMVD2019
  4. BENCH canine CHF trial1999
  5. QUEST pimobendan vs benazepril2008
  6. BESST combination trial2021
  7. BENCH canine tolerability2004
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Potential oral use of this unidentified generic benazepril tablet to reduce persistent renal proteinuria associated with feline chronic kidney disease
Not rateable
No numerical score assigned
vetman assessment

Benazepril 5 mg

tablet
Assessed clinical scopeCat · Potential oral use of this unidentified generic benazepril tablet to reduce persistent renal proteinuria associated with feline chronic kidney disease · By mouth
Care settingVeterinary-directed long-term treatment only after persistent renal proteinuria is confirmed and dehydration is corrected, with serial UPC, blood pressure, creatinine/SDMA, electrolytes and clinical response monitoring.
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: No · Verified on 15 Oct 2026 Off-label use
Not rateable

A numerical product score cannot be assigned because catalogue entry 9112 identifies only a generic 5 mg benazepril tablet. It gives no trade name, manufacturer or marketing-authorisation holder, authorisation number, pack, exact label or independently verified formulation. Its dose records explicitly borrow the BenazeVet SPC as a comparator. BenazeVet has applicable dog/cat authorisations and substantial clinical evidence, but those facts cannot be transferred to an unidentified tablet to score its regulation, safety, subdivision, palatability, storage or practical dose delivery. Confirm the exact marketed product or convert this record to a verified BenazeVet presentation before numerical scoring.

Benazepril can reduce proteinuria in cats with CKD and is included among RAAS-inhibitor options, but an all-cat survival benefit has not been shown and telmisartan has stronger comparative UPC results. That ingredient-level judgment does not identify or validate this tablet.

Important safety and use flags

  • Exact product identity is missing. Do not infer manufacturer, authorisation, bioequivalence, excipients, flavouring, pack or quality from the generic catalogue name.
  • BenazeVet is the documented clinical and dosing comparator, not the identified product in this catalogue row. Its authorisation and product-specific properties must not be represented as belonging to this unidentified tablet.
  • In cats, the supported role is reduction of persistent renal proteinuria associated with CKD, not general treatment of every cat with CKD, not stand-alone control of systemic hypertension and not a proven survival-extending claim.
  • Feline trials support reduction in UPC, but the largest placebo-controlled study did not show a significant overall renal-survival benefit. In an active-comparator trial telmisartan was noninferior and produced significant UPC reductions where benazepril did not.
  • Do not start an ACE inhibitor in a dehydrated, hypovolaemic or haemodynamically unstable patient. Correct volume deficits first; monitor blood pressure, hydration, creatinine/SDMA, urea and electrolytes after initiation and dose changes.
  • Do not use with hypotension, hypovolaemia, hyponatraemia, acute renal failure, hypersensitivity, or cardiac-output failure caused by aortic or pulmonary stenosis. Safety and efficacy are not established below 2.5 kg for the BenazeVet comparator.
  • Do not use during pregnancy or lactation. Breeding safety is not established and ACE inhibition has recognised fetal risk; prevent accidental ingestion, especially by pregnant people and children.
  • Review NSAIDs, other hypotensive medicines, anaesthetics/sedatives and potassium-sparing diuretics. Monitor renal function, hypotension and potassium; do not assume absence of an interaction merely because common CHF combinations have been used.
  • This generic 5 mg row is marked as a scored tablet, but exact equal subdivision, palatability, half-tablet shelf life and storage are properties of a verified formulation. Do not transfer those BenazeVet features until the actual product is identified.
Assessment sources
  1. Benazepril identity audit2026
  2. BenazeVet 5 mg, VMD SPC 20252025
  3. IRIS 20262026
  4. BENRIC feline CKD trial2006
  5. Feline CKD efficacy trial2006
  6. Telmisartan-benazepril feline trial2015
  7. Feline renal PK/PD2002
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Benazepril5 mg
Formulation Type
Scored tablet
Administration route
By mouth
Manufacturer
-
Product
generic presentation, not registered in Georgia under a trade name
Registration
Georgia No
Not registered in Georgia
Veterinary (National Food Agency)
Verified on: 15 Oct 2026
 EU Not confirmed
Verified on: 15 Oct 2026
 UK Not confirmed
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 22 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗